176 related articles for article (PubMed ID: 11863116)
21. Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
Slichenmyer WJ; Fry DW
Semin Oncol; 2001 Oct; 28(5 Suppl 16):67-79. PubMed ID: 11706398
[TBL] [Abstract][Full Text] [Related]
22. [Management of metastatic HER2-positive breast cancer: present and future].
Guiu S; Coudert B; Favier L; Arnould L; Fumoleau P
Bull Cancer; 2010 Mar; 97(3):365-83. PubMed ID: 20176546
[TBL] [Abstract][Full Text] [Related]
23. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Ahmed S; Sami A; Xiang J
Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
[TBL] [Abstract][Full Text] [Related]
24. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
[TBL] [Abstract][Full Text] [Related]
25. [New treatment approaches in breast cancer].
Spirig C; Thürlimann B; Huober J
Ther Umsch; 2008 Apr; 65(4):207-10. PubMed ID: 18622912
[TBL] [Abstract][Full Text] [Related]
26. HER2 as a cancer stem-cell target.
Roesler R; Cornelio DB; Abujamra AL; Schwartsmann G
Lancet Oncol; 2010 Mar; 11(3):225-6. PubMed ID: 20202610
[No Abstract] [Full Text] [Related]
27. POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
Goel S; Winer EP
Oncology (Williston Park); 2015 Nov; 29(11):797-8, 802. PubMed ID: 26573058
[No Abstract] [Full Text] [Related]
28. Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?
Normanno N; Campiglio M; Perrone F; De Luca A; Menard S
Ann Oncol; 2005 Oct; 16(10):1709. PubMed ID: 16150806
[No Abstract] [Full Text] [Related]
29. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
Eniu A
J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
[TBL] [Abstract][Full Text] [Related]
30. Lapatinib plus capecitabine in breast cancer.
Sonpavde G
N Engl J Med; 2007 Apr; 356(14):1471; author reply 1471-2. PubMed ID: 17409332
[No Abstract] [Full Text] [Related]
31. Targeting alternative pathways in HER2-positive breast cancer.
Rastogi P
Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739
[No Abstract] [Full Text] [Related]
32. Lapatinib in breast cancer: clinical experiences and future perspectives.
Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
[TBL] [Abstract][Full Text] [Related]
33. HER2-positive breast cancer: current and future treatment strategies.
Engel RH; Kaklamani VG
Drugs; 2007; 67(9):1329-41. PubMed ID: 17547474
[TBL] [Abstract][Full Text] [Related]
34. Ten years of HER2-directed therapy: still questions after all these years.
Krop IE; Winer EP
Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974
[No Abstract] [Full Text] [Related]
35. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
[No Abstract] [Full Text] [Related]
36. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Cameron D
Clin Adv Hematol Oncol; 2007 Jun; 5(6):456-8. PubMed ID: 17679920
[No Abstract] [Full Text] [Related]
37. [Breast cancer].
Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
[TBL] [Abstract][Full Text] [Related]
38. HER2 testing in patients with breast cancer.
Dixon JM; Wilson V; Verrill M; Symmans WF
BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887
[No Abstract] [Full Text] [Related]
39. HER2-positive breast cancer: beyond trastuzumab.
Murphy CG; Fornier M
Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
[TBL] [Abstract][Full Text] [Related]
40. [Combined anti-EGFR and anti-HER2 monoclonal antibodies: preclinical efficacy in the treatment of pancreatic cancer].
Larbouret C; Robert B; Teulon I; Azria D; Pèlegrin A
Med Sci (Paris); 2007 Oct; 23(10):800-3. PubMed ID: 17937885
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
